Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Sinha, Sanjeev ^a   Shekhar, Rahul C ^a   Singh, Gurjeet ^a   Shah, Nipam ^a   Ahmad, Hafiz ^a   Kumar, Narendra ^a   Sharma, Surendra K ^a   Samantaray, J C ^a   Ranjan, Sanjai ^a   Ekka, Meera ^a   Sreenivas, Vishnu ^a   Mitsuyasu, Ronald T ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral; Delayed; Early; HIV; Tuberculosis

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; STEROID; STREPTOMYCIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY INTERVENTION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INDIAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PNEUMOCYSTOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; THERAPY DELAY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INDIA; MALE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE; TUBERCULOSIS;

EID: 84866615459     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-168     Document Type: Article

References (35)

1. The United Nations Joint Programme on HIV/AIDS (UNAIDS) 2010 report on the global HIV/AIDS epidemic. 2010, UNAIDS. Technical Report number: UNAIDS/10.11E, Geneva, The United Nations Joint Programme on HIV/AIDS (UNAIDS).
2. World Health Organization (WHO) HIV/AIDS: Tuberculosis and HIV [Internet] 2011, Available from: http://www.who.int/hiv/topics/tb/en/index.html (accessed April 13), World Health Organization (WHO).
3. WHO Global Tuberculosis Control. WHO report 2010, WHO.
4. UNAIDS HIV Data: Epidemiology Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/Epidemiology/latestEpiData.asp (accessed April 8, 2011), UNAIDS.
5. Revised National Tuberculosis Control Programme (RNTCP) TB India 2010: RNTCP Status Report 2010, Ministry of Health and Family Welfare, Government of India, New Delhi, Revised National Tuberculosis Control Programme (RNTCP).
6. National AIDS Control Organization (NACO) 2009-2010: Annual Status report 2010, Department of AIDS Control, Ministry of Health and Family Welfare, Govt. of India, New Delhi, National AIDS Control Organization (NACO).
7. Charles LD, Peter MS, Gisela FS, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992, 326(4):231-235. 10.1056/NEJM199201233260404, 1345800.
8. De Cock KM, Soro B, Coulibaly IM, et al. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992, 268:1581-1587. 10.1001/jama.1992.03490120095035, 1518113.
9. Wilkinson D, Moore DAJ. HIV-related tuberculosis in South Africa-clinical features and outcome. S Afr Med J 1996, 86(1):64-67.
10. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359(9323):2059-2064. 10.1016/S0140-6736(02)08904-3, 12086758.
11. Sanguanwongse N, Cain KP, Suriya P, et al. Antiretroviral therapy for HIV -infected Tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 2008, 48(2):181-189. 10.1097/QAI.0b013e318177594e, 18520676.
12. Piggott DA, Karakousis PC. Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol [Internet] 2010, 2011:103917. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017895/(accessed April 5, 2011) DOI:.
13. ACTG A5221. Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis 2011, Available at: http://clinicaltrials.gov/ct2/show/NCT00108862 (accessed March 31).
14. World Health Organization Treatment of Tuberculosis: Guidelines 2010, WHO, 4, World Health Organization.
15. NACO HIV Testing policy and functioning of VCTC 2001, New Delhi, Ministry of Health and Family welfare, Govt. of India, NACO.
16. NACO National AIDS Prevention and Control Policy 2002, New Delhi, Ministry of Health and Family Welfare, Govt. of India, NACO.
17. NACO Antiretroviral Therapy guidelines for HIV infected adults and adolescents including post exposure prophylaxis 2007, Ministry of Health and Family Welfare, Govt. of India, New Delhi, NACO.
18. WHO Tuberculosis: Definitions of Tuberculosis cases and treatment outcomes 2011, Available at: http://www.who.int/tb/publications/global_report/2007/table 5/en/index1.html (accessed March 31), WHO.
19. National Institute of Allergy and Infectious Diseases (NIAID) NIH-funded study finds early HAART during TB treatment boosts survival rate in people co-infected with HIV and TB 2010, NIH News, National Institute of Allergy and Infectious Diseases (NIAID).
20. WHO TB/HIV Working Group. Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings 2010, World Health Organization, WHO.
21. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007, 196(suppl 1):S46-S51.
22. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during Tuberculosis therapy. N Engl J Med 2010, 362(8):697-706. 10.1056/NEJMoa0905848, 3076221, 20181971.
23. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in Survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis 2010, 18-23. Presented at: Proceedings of the XVIII International AIDS Society Conference, Vienna, Austria. (Abstract THLBB106).
24. Zargoza-Marcias E, Cosco D, Nguyen ML, et al. Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population. AIDS Res Hum Retroviruses 2010, 26(2):133-138. 10.1089/aid.2009.0001, 2858896, 20156096.
25. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiationg triple -drug therapy. JAMA 2001, 286(20):2568-2577. 10.1001/jama.286.20.2568, 11722271.
26. Jaen A, Esteve A, Miro JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47(2):212-220. 10.1097/QAI.0b013e31815ee282, 18297762.
27. Whalen C, Okwera A, Johnson J, et al. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med 1996, 153:1977-1981.
28. Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000, 14(9):1219-1228. 10.1097/00002030-200006160-00020, 2869086, 10894287.
29. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003, 188(8):1146-1155. 10.1086/378676, 14551885.
30. Morris L, Martin DJ, Bredell H, et al. Human Immunodeficiency Virus1 RNA Levels and CD4 Lymphocyte Counts, during Treatment for Active Tuberculosis, in South African Patients. J Infect Dis 2003, 187(12):1967-1971. 10.1086/375346, 12792875.
31. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997, 155(3):996-1003.
32. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43(1):42-46. 10.1097/01.qai.0000230521.86964.86, 16885778.
33. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992, 146(4):849-854.
34. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000, 4:705-712.
35. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents 2010, WHO, World Health Organization.